Brand and Other Names:Cognex
Dosing & Uses
Dosage Forms & Strengths
10-20 mg PO QID; no more than 160 mg/day
Monitor LFTs every other week from weeks 4-16, then q3Months
Take between meals, unless GI upset
LFTs >3-5x upper limit of normal, reduce dose to 10mg PO QID, monitor LFT's qWeek, resume dose titration and qoWeek monitoring when ALT return to normal
LFT's >5x upper limit of normal, stop treatment monitor for symptom hepatitis, follow ALT until WNL's and rechallenge with initial dose 10 mg PO QID, monitor LFT's qweek, if after 6 weeks ALT wnl's may retry dose titration schedule, continue qweek ALT monitoring for 16 weeks then qmonths for 2 months then q3Months thereafter
<18 years old: Safety & efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Incr LFT's (26-30%)
Abdominal pain (6-10%)
Weight loss (1-5%)
Drug-induced bilirubin >3 mg/dL [51.3 umol/L]
Pregnancy & Lactation
Pregnancy Category: C
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Half-Life: 2-4 hr
Peak Plasma Time: 1-2 hr
Protein Bound: 55%
Vd: 349 L
Metabolism: hepatic P450 enzyme CYP1A2
Enzymes inhibited: CYP1A2
Mechanism of Action
Centrally acting cholinesterase inhibitor